WO2013124740A3 - Dysfonctionnement de la protéine brca et signatures arnm utiles dans l'identification de patients atteints de tumeurs dues au dysfonctionnement de la protéine brca et prévision des bénéfices d'une thérapie anti-cancer sur des patients atteints de cancer - Google Patents

Dysfonctionnement de la protéine brca et signatures arnm utiles dans l'identification de patients atteints de tumeurs dues au dysfonctionnement de la protéine brca et prévision des bénéfices d'une thérapie anti-cancer sur des patients atteints de cancer Download PDF

Info

Publication number
WO2013124740A3
WO2013124740A3 PCT/IB2013/000670 IB2013000670W WO2013124740A3 WO 2013124740 A3 WO2013124740 A3 WO 2013124740A3 IB 2013000670 W IB2013000670 W IB 2013000670W WO 2013124740 A3 WO2013124740 A3 WO 2013124740A3
Authority
WO
WIPO (PCT)
Prior art keywords
brca
patients
cancer
identification
deficient tumors
Prior art date
Application number
PCT/IB2013/000670
Other languages
English (en)
Other versions
WO2013124740A2 (fr
Inventor
Cornelia Ramona Jimenez
Marc Omer WARMOES
Thang Viet PHAM
Sven ROTTENBERG
Original Assignee
Stichting Vu-Vumc
Stichting Het Nederlands Kanker Instituut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stichting Vu-Vumc, Stichting Het Nederlands Kanker Instituut filed Critical Stichting Vu-Vumc
Publication of WO2013124740A2 publication Critical patent/WO2013124740A2/fr
Publication of WO2013124740A3 publication Critical patent/WO2013124740A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention concerne des signatures du dysfonctionnement du gène BRCA comprenant des protéines régulées de manière différentielle présentes dans des tumeurs dues au dysfonctionnement du gène BRCA1, et des signatures du dysfonctionnement du gène BRCA comprenant des acides nucléiques isolés des tumeurs dues au dysfonctionnement du gène BRCA1, ainsi que des méthodes d'utilisation de celles-ci.
PCT/IB2013/000670 2012-02-23 2013-02-25 Dysfonctionnement de la protéine brca et signatures arnm utiles dans l'identification de patients atteints de tumeurs dues au dysfonctionnement de la protéine brca et prévision des bénéfices d'une thérapie anti-cancer sur des patients atteints de cancer WO2013124740A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261602383P 2012-02-23 2012-02-23
US61/602,383 2012-02-23

Publications (2)

Publication Number Publication Date
WO2013124740A2 WO2013124740A2 (fr) 2013-08-29
WO2013124740A3 true WO2013124740A3 (fr) 2014-01-09

Family

ID=48325788

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2013/000670 WO2013124740A2 (fr) 2012-02-23 2013-02-25 Dysfonctionnement de la protéine brca et signatures arnm utiles dans l'identification de patients atteints de tumeurs dues au dysfonctionnement de la protéine brca et prévision des bénéfices d'une thérapie anti-cancer sur des patients atteints de cancer

Country Status (1)

Country Link
WO (1) WO2013124740A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9982307B2 (en) 2012-06-13 2018-05-29 King Abdullah University Of Science And Technology Methylation biomarkers for breast cancer
WO2015100257A1 (fr) * 2013-12-23 2015-07-02 The General Hospital Corporation Procédés et dosages pour la détermination d'une fonction de voie brca1 réduite dans une cellule cancéreuse
US20180148792A1 (en) 2015-05-19 2018-05-31 T.S. Sridhar Method for Identification of a Deficient BRCA1 Function
CA3074985A1 (fr) 2017-10-16 2019-04-25 Dana-Farber Cancer Institute, Inc. Composes et procedes de traitement du cancer
KR102368717B1 (ko) * 2018-11-16 2022-02-28 가톨릭대학교 산학협력단 유전성 난소암 발병 예측용 바이오마커 및 이의 용도

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5721098A (en) 1986-01-16 1998-02-24 The Regents Of The University Of California Comparative genomic hybridization
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
EP1134293A3 (fr) 1992-03-04 2004-01-07 The Regents of The University of California Hybridation génomique comparative
US5965362A (en) 1992-03-04 1999-10-12 The Regents Of The University Of California Comparative genomic hybridization (CGH)
DE4344726C2 (de) 1993-12-27 1997-09-25 Deutsches Krebsforsch Verfahren zum Nachweis von nicht balanciertem genetischen Material einer Spezies oder zum Nachweis der Genexpression in Zellen einer Spezies
US5830645A (en) 1994-12-09 1998-11-03 The Regents Of The University Of California Comparative fluorescence hybridization to nucleic acid arrays
US5635351A (en) 1995-03-14 1997-06-03 The Regents Of The University Of California Genetic gain and loss in gliomas
WO1996039154A1 (fr) 1995-06-06 1996-12-12 Isis Pharmaceuticals, Inc. Oligonucleotides de grande purete chirale ayant des liaisons phosphorothioate
US5985662A (en) 1995-07-13 1999-11-16 Isis Pharmaceuticals Inc. Antisense inhibition of hepatitis B virus replication
US6251601B1 (en) 1999-02-02 2001-06-26 Vysis, Inc. Simultaneous measurement of gene expression and genomic abnormalities using nucleic acid microarrays

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
ATALAY A ET AL: "Identification of genes induced by BRCA1 in breast cancer cells", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 299, no. 5, 20 December 2002 (2002-12-20), pages 839 - 846, XP002972619, ISSN: 0006-291X, DOI: 10.1016/S0006-291X(02)02751-1 *
FRANK WEBER ET AL: "Total-Genome Analysis of BRCA1/2-Related Invasive Carcinomas of the Breast Identifies Tumor Stroma as Potential Landscaper for Neoplastic Initiation", THE AMERICAN JOURNAL OF HUMAN GENETICS, vol. 78, no. 6, 1 June 2006 (2006-06-01), pages 961 - 972, XP055078937, ISSN: 0002-9297, DOI: 10.1086/504090 *
JAZAERI A A ET AL: "GENE EXPRESSION PROFILES OF BRCA1-LINKED, BRCA2-LINKED, AND SPORADIC OVARIAN CANCERS", JOURNAL OF THE NATIONAL CANCER INSTITUTE, OXFORD UNIVERSITY PRESS, GB, vol. 94, no. 13, 3 July 2002 (2002-07-03), pages 990 - 1000, XP009058700, ISSN: 0027-8874 *
LAURA J VAN 'T VEER ET AL: "Gene Expression Profiling Predicts Clinical Outcome of Breast Cancer", NATURE: INTERNATIONAL WEEKLY JOURNAL OF SCIENCE, NATURE PUBLISHING GROUP, UNITED KINGDOM, vol. 415, no. 6871, 31 January 2002 (2002-01-31), pages 530 - 536, XP008138701, ISSN: 0028-0836, DOI: 10.1038/415530A *
M. A. VOLLEBERGH ET AL: "An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients", ANNALS OF ONCOLOGY, vol. 22, no. 7, 1 July 2011 (2011-07-01), pages 1561 - 1570, XP055031907, ISSN: 0923-7534, DOI: 10.1093/annonc/mdq624 *
M. WARMOES ET AL: "Proteomics of Mouse BRCA1-deficient Mammary Tumors Identifies DNA Repair Proteins with Potential Diagnostic and Prognostic Value in Human Breast Cancer", MOLECULAR & CELLULAR PROTEOMICS, vol. 11, no. 7, 24 February 2012 (2012-02-24), XP055070274, ISSN: 1535-9476, DOI: 10.1074/mcp.M111.013334 *
MANUELA SANTAROSA ET AL: "BRCA1 modulates the expression of hnRNPA2B1 and KHSRP", CELL CYCLE, vol. 9, no. 23, 1 December 2010 (2010-12-01), pages 4666 - 4673, XP055070584, ISSN: 1538-4101, DOI: 10.4161/cc.9.23.14022 *
P. A. KONSTANTINOPOULOS ET AL: "Gene Expression Profile of BRCAness That Correlates With Responsiveness to Chemotherapy and With Outcome in Patients With Epithelial Ovarian Cancer", JOURNAL OF CLINICAL ONCOLOGY, vol. 28, no. 22, 14 June 2010 (2010-06-14), pages 3555 - 3561, XP055070579, ISSN: 0732-183X, DOI: 10.1200/JCO.2009.27.5719 *
SIMON A JOOSSE ET AL: "Prediction of BRCA1-association in hereditary non-BRCA1/2 breast carcinomas with array-CGH", BREAST CANCER RESEARCH AND TREATMENT, KLUWER ACADEMIC PUBLISHERS, BO, vol. 116, no. 3, 14 August 2008 (2008-08-14), pages 479 - 489, XP019727887, ISSN: 1573-7217 *
SIMON A. JOOSSE ET AL: "Genomic signature of BRCA1 deficiency in sporadic basal-like breast tumors", GENES, CHROMOSOMES AND CANCER, vol. 50, no. 2, 22 February 2011 (2011-02-22), pages 71 - 81, XP055070299, ISSN: 1045-2257, DOI: 10.1002/gcc.20833 *
STEFANIA MILLEVOI ET AL: "The c.5242C>A BRCA1 missense variant induces exon skipping by increasing splicing repressors binding", BREAST CANCER RESEARCH AND TREATMENT, KLUWER ACADEMIC PUBLISHERS, BO, vol. 120, no. 2, 30 April 2009 (2009-04-30), pages 391 - 399, XP019787437, ISSN: 1573-7217 *
STEPHEN BECKER ET AL: "Surfaced-Enhanced Laser Desorption/Ionization Time-of-Flight (SELDI-TOF) Differentiation of Serum Protein Profiles of BRCA-1 and Sporadic Breast Cancer", ANNALS OF SURGICAL ONCOLOGY, SPRINGER-VERLAG, NE, vol. 11, no. 10, 1 January 2004 (2004-01-01), pages 907 - 914, XP019369397, ISSN: 1534-4681 *

Also Published As

Publication number Publication date
WO2013124740A2 (fr) 2013-08-29

Similar Documents

Publication Publication Date Title
TWI799368B (zh) 抗ｔｌ１ａ抗原結合蛋白及相關核酸、表現載體、宿主細胞、醫藥組合物、方法及用途
BR112014006158A2 (pt) molécula de ligação, molécula de ácido nucléico, vetor, célula hospedeira, processo para preparar uma molécula de ligação, métodos para acentuar uma resposta imune em um indivíduo humano, para tratar câncer em um indivíduo humano em necessidade do mesmo, para reduzir o tamanho de um tumor ou inibir o crescimento de células cancerosas em um indivíduo ou reduzir ou inibir o desenvolvimento do câncer metastático em um indivíduo sofrendo de câncer, uso de uma molécula de ligação, e, composição farmacêutica
EP3337909A4 (fr) Procédés et réactifs pour la détection de la proximité moléculaire à l'aide de protéines de liaison d'acide nucléique guidées par l'arn
SG10201807838SA (en) Determining cancer aggressiveness, prognosis and responsiveness to treatment
WO2014031487A8 (fr) Inhibiteurs bivalents de protéines iap et méthodes thérapeutiques les utilisant
WO2013170170A3 (fr) Compositions et méthodes de thérapie génique
WO2012177595A9 (fr) Compositions et méthodes pour la thérapie et le diagnostic du cancer
MX2015008446A (es) Composiciones de proteinas de union multivalentes.
WO2011143656A3 (fr) Compositions et procédés d'identification de néoantigènes spécifiques à une tumeur
WO2015070020A3 (fr) Polythérapie pour le traitement du cancer utilisant des inhibiteurs de protéine à bromodomaine et à domaine extra-terminal (bet)
WO2014018563A3 (fr) Procédés pour le traitement du cancer
WO2015031771A3 (fr) Administration d'enzymes de déplétion de kynurénine pour le traitement d'une tumeur
WO2011106300A3 (fr) Thérapie anti-angiogénique pour le traitement du cancer des ovaires
WO2014018673A3 (fr) Protéines de fusion et leurs procédés associés
BR112012020373A8 (pt) anticorpo isolado, célula, ácido nucleico isolado, método de identificação, de inibição da proliferação de uma célula, de tratamento terapêutico, de determinação da presença de uma proteína tat419, de diagnóstico da presença de câncer e de distribuição de agente citotóxico
WO2014106459A3 (fr) Procédé de traitement d'une tumeur en utilisant un interféron recombinant avec une configuration spatiale modifiée
WO2013124740A3 (fr) Dysfonctionnement de la protéine brca et signatures arnm utiles dans l'identification de patients atteints de tumeurs dues au dysfonctionnement de la protéine brca et prévision des bénéfices d'une thérapie anti-cancer sur des patients atteints de cancer
WO2012138789A3 (fr) Procédés et compositions pour prédire une résistance à un traitement anti-cancéreux
WO2014011489A3 (fr) Anticorps monoclonaux pour l'utilisation dans le diagnostic et la thérapie de cancers et d'une maladie auto-immune
WO2007100859A3 (fr) Prédicteurs de gènes de la réponse à la chimiothérapie des métastases colorectales
WO2013177593A3 (fr) Identification d'antigènes phosphopeptidiques de cmh de classe i du cancer du sein à l'aide d'une technologie shla et de stratégies d'enrichissement complémentaires
EP4269427A3 (fr) Interfaces de protéines
WO2013124738A3 (fr) Méthodes et biomarqueurs permettant de dépister et de pronostiquer le cancer du col utérin
WO2015001013A3 (fr) Anticorps anti-ifn-alpha humains
EP3444351A4 (fr) Aptamère d'acide ribonucléique présentant un effet inhibiteur sur le cancer du poumon à non petites cellules, et composition pharmaceutique le comprenant

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13721057

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 13721057

Country of ref document: EP

Kind code of ref document: A2